A Phase IIa, Randomised, Parallel, Double-Blind,Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2019
At a glance
- Drugs MEDI 0382 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 29 Jan 2019 Status changed from active, no longer recruiting to completed.
- 20 Dec 2018 Planned End Date changed from 6 Dec 2018 to 23 Jan 2019.
- 20 Dec 2018 Planned primary completion date changed from 6 Dec 2018 to 23 Jan 2019.